tDCS and Inhibitory Control in PTSD - Trial NCT06100731
Access comprehensive clinical trial information for NCT06100731 through Pure Global AI's free database. This phase not specified trial is sponsored by University of Kentucky and is currently Recruiting. The study focuses on Post Traumatic Stress Disorder. Target enrollment is 100 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
University of Kentucky
Timeline & Enrollment
N/A
Oct 27, 2023
Dec 18, 2024
Primary Outcome
Stop Signal Reaction Time (SSRT),Skin conductance level (SCL),Heart Rate (HR)
Summary
Large samples (~2,000/yr) of adult undergraduate students at a large southern university will
 be pre-screened via the University of Kentucky SONA System (IRB#43626) to identify and
 recruit adult female participants who report a history of IPV and probable PTSD to
 participate in a one-day lab study. After completing an IRB-approved informed consent,
 participants will complete a brief psychiatric diagnostic interview and a battery of
 questionnaires. They will then complete three blocks of the Stop Signal Task (SST).
 Participants will be randomized (double-blind, stratified by PTSD diagnosis and psychotropic
 medication use) to receive 15-min of active or sham multifocal tDCS targeting the rIFG. tDCS
 will be delivered offline for 11.5-mins after block 1 of the SST and online for 3.5-mins
 during block 2 of the SST. Sham stimulation will be identical to active tDCS, but electrical
 current will only be ramped in/out at the beginning and end of the 15-mins. The third block
 of the SST will be completed after tDCS. Lastly, participants will complete a pictorial
 trauma-related symptom provocation task. Participants will be compensated with course credit.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06100731
Device Trial